Studies from University of Nebraska Medical Center Update Current Data on Factor Xa Inhibitors (Lower Mortality With Andexanet Alfa Vs 4-factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-related Major Bleeding In a Us...).

A recent study conducted at the University of Nebraska Medical Center compared the effectiveness of andexanet alfa and 4-factor prothrombin complex concentrate (4F-PCC) in treating major bleeding caused by factor Xa inhibitors. The study analyzed data from 354 hospitals in the United States and included 4,395 patients. The results showed that patients treated with andexanet alfa had a 50% lower risk of in-hospital mortality compared to those treated with 4F-PCC. This risk reduction was consistent for both intracranial hemorrhage and gastrointestinal bleeds. The study suggests that andexanet alfa may be a more effective treatment option for major bleeding caused by factor Xa inhibitors. [Extracted from the article]